Jun 12, 2021, 7:52 PM
Journalist ID: 3080
News Code: 84364056
1 Persons

Tags

2nd dose of Pasteurcovac's injection to be end in coming days

Tehran, June 12, IRNA - The project manager of the third phase of the joint COVID-19 vaccine clinical trial between Iran and Cuba Ehsan Mostafavi said on Saturday that the injection of the second dose of the Iran-Cuba joint vaccine will end in the coming days.

Mostafavi said that the number of volunteers in the third phase of human testing of the Iran-Cuba joint vaccine is 24,000 and so far over 14,500 volunteers have received the second dose of their vaccine.

He noted that the Iran-Cuba vaccine will be branded "Pasteurcovac" after production at Pasteur Institute of Iran.

The vaccine is jointly produced by the Pasteur Institute of Iran (IPI) and the Finlay Institute of Vaccines of Cuba.

Some 24,000 volunteers from different Iranian cities of Isfahan, Babol, Bandar Abbas, Zanjan, Sari, Kerman, Hamedan, and Yazd have taken part in the third phase trial.

The volunteers are ages 18 to 80.

After finally being confirmed by IPI, National Vaccination Campaign will start.

Since its outbreak worldwide in December 2019, the coronavirus has killed over 3,100,000, while the number of the dead in Iran has passed 81,900.

3266**7129

Follow us on Twitter @IrnaEnglish

Your Comment

You are replying to: .
captcha